Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 15/20 | 0.80 |
| ▸ | ABL1 | P00519 | 8/20 | 0.80 |
| ▸ | EGFR | P00533 | 8/20 | 0.80 |
| ▸ | ABL2 | P42684 | 8/20 | 0.80 |
| ▸ | RIPK2 | O43353 | 4/20 | 0.77 |
| ▸ | LCK | P06239 | 4/20 | 0.72 |
| ▸ | TEK | Q02763 | 2/20 | 0.72 |
| ▸ | HCK | P08631 | 1/20 | 0.72 |
| ▸ | RET | P07949 | 2/20 | 0.63 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.63 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.63 |
| ▸ | FLT1 | P17948 | 2/20 | 0.63 |
| ▸ | KDR | P35968 | 2/20 | 0.63 |
| ▸ | FLT3 | P36888 | 2/20 | 0.63 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.63 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.63 |
| ▸ | FYN | P06241 | 1/20 | 0.63 |
| ▸ | LTK | P29376 | 1/20 | 0.63 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.63 |
| ▸ | CDK8 | P49336 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6868903 | 0.93 | SRC (0.73) | SRCABL1EGFRABL2RIPK2 | |
| SCHEMBL20351800 | 0.91 | SRC (0.74) | SRCABL1EGFRABL2RIPK2 | |
| SCHEMBL8108273 | 0.88 | SRC (0.70) | SRCABL1EGFRABL2RIPK2 | |
| SCHEMBL7020106 | 0.86 | SRC (0.87) | SRCABL1EGFRABL2RIPK2 | |
| SCHEMBL8098913 | 0.84 | SRC (0.63) | SRCABL1EGFRABL2RIPK2 | |
| SCHEMBL20351598 | 0.84 | SRC (0.76) | SRCABL1EGFRABL2RIPK2 | |
| SCHEMBL6466052 | 0.84 | LCK (1.00) | SRCABL1EGFRLCKTEK | |
| SCHEMBL6865566 | 0.82 | SRC (0.79) | SRCABL1EGFRABL2RIPK2 | |
| SCHEMBL8107249 | 0.82 | SRC (0.80) | SRCABL1EGFRABL2RIPK2 | |
| SCHEMBL7019904 | 0.82 | SRC (1.00) | SRCABL1EGFRABL2RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170158697-A1 | Protein Kinase Inhibitors | PHARMASCIENCE INC. (CA) | 2017-06-08 | — | — | US | disclosed |
| US-20170158697-A1 | Protein Kinase Inhibitors | PHARMASCIENCE INC. (CA) | 2017-06-08 | — | — | US | disclosed |
| WO-2015077866-A1 | PROTEIN KINASE INHIBITORS | PHARMASCIENCE INC. (CA) | 2015-06-04 | — | — | WO | disclosed |
| US-6713474-B2 | SERINE-THREONINE AND TYROSINE KINASE INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2004-03-30 | — | — | US | disclosed |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-08-14 | — | — | US | disclosed |
| EP-1114053-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000017203-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | FLT1, FLT4, TFPI | SRC 206/4885ABL1 78/4885EGFR 457/4885 |
| US-20170158697-A1 | Protein Kinase Inhibitors | TEC, LCK, SRC | SRC 3/4885ABL1 27/4885EGFR 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.